Trends in peptic ulcer pharmacotherapy

Fundamental and Clinical Pharmacology

Volumn 18, Issue 1, 2004, Pages 23-31

  Sivri, Bülent ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

H. pylori; NonHp NonNSAID ulcer; NSAID related ulcer; Peptic ulcer; Pharmacotherapy

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; CISAPRIDE; CLARITHROMYCIN; CYCLOOXYGENASE 2 INHIBITOR; ESOMEPRAZOLE; LANSOPRAZOLE; LICOFELONE; MACROLIDE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN G; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE BISMUTH CITRATE; TERFENADINE; TETRACYCLINE; TINIDAZOLE;

ANAMNESIS; BACTERIAL INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DIARRHEA; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ERADICATION THERAPY; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; IMMUNOSTIMULATION; LIVER TOXICITY; NEPHROTOXICITY; PATHOPHYSIOLOGY; PATIENT INFORMATION; PENICILLIN ALLERGY; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SYMPTOMATOLOGY;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 1042299810     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2004.00203.x     Document Type: Review

References (64)

1. Modlin I.M., Sachs G. Acid related diseases - biology and treatment, Schnetztor-Verlag GmbH D-Konstanz, Milano, 1998.
2. Warren J.R., Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis (letter). Lancet (1983) 1 1273.
3. Clancy R.L., Pang G. Is there another chapter in the Helicobacter pylori/peptic ulcer disease story? Int. Med. J. (2001) 31 181-183.
4. Goldshall C.J. Treatment ofHelicobacter pylori infection in patients with peptic ulcer disease. Am. J. Surgery (2002) 183 2-3.
5. Isenberg J.I., Soll A.H. Epidemiology, clinical manifestations, and diagnosis of peptic ulcer, in: Bennett J.C., Plum F. (Eds). Cecil textbook of medicine, Saunders, Philadelphia, PA, 1996, pp. 664-666.
6. Go M.F. Review article: natural history and epidemiology of Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2002) 16 3-15.
7. Vandenplas Y. Helicobacter pylori infection. World J. Gastroenetrol. (2000) 6 20-31.
8. Cohen H. Peptic ulcer and Helicobacter pylori. Gastroenterol. Clin. North Am. (2000) 29 775-789.
9. Graham D.Y., Rakel R.E., Fendrick A.M. et al. Scope and consequences of peptic ulcer disease. How important is asymptomatic Helicobacter pylori infection? Postgrad. Med. (1999) 105(3) 100-2, 105-8, 110.
10. Vaira D., Holton J., Ricci C, et al. Review article: Helicobacter pylori infection from pathogenesis to treatment - a critical reappraisal. Aliment. Pharmacol. Ther. (2002) 16 (Suppl. 4) 105-113.
11. Spiro H.M. Peptic ulcer: Moynihan's or Marshall's disease? Lancet (1998) 352 645-646.
12. Huang J., Sridhar S., Hunt R.H. Role of Helicobacter pylori infection and non-steroidal antiinflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet (2002) 359 14-22.
13. Fennerty M.B. NSAID-related gastrointestinal injury. Evidence based approach to a preventable complication. Postgrad. Med. (2001) 110 87-94.
14. Howden C.W., Leontiadis G.I. Current indications for acid suppressants in Helicobacter pylori-negative ulcer disease. Best Practice & Research Clinical Gastroenterology (2001) 15 401-412.
15. Shiotani A., Graham D.Y. Pathogenesis and therapy of gastric and duodenal ulcer disease. Med. Clin. North Am. (2002) 86 1447-1466.
16. Graham D.Y., Rakel R.E., Fendrick A.M. et al. Recognizing peptic ulcer disease. Keys to clinical and laboratory diagnosis. Postgrad. Med. (1999) 105 145-148
17. Mc Loughlin R.M., Sebastian S.S., O'Connor H.J. et al. Review article: test and treat or test and scope for Helicobacter pylori infection. Any change in gastric cancer prevention? Aliment. Pharmacol. Ther. (2003) 17 (Suppl. 2) 82-88.
18. Howden C.W., Hunt R.H. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am. J. Gastroenterol. (1998) 93 2330-2338.
19. Malfertheiner P., Mégraud F., O'Morain C, et al. Current concept in the management of Helicobacter pylori infection - The Maastricht 2-2000 Concensus Report. Aliment. Pharmacol. Ther. (2002) 16 167-180.
20. American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology (1998) 114 579-581.
21. Talley N.J. Dyspepsia management in the millenium: the death of test and treat? Gastroenterology (2002) 122 1521-1525.
22. Al-Eidan F.A., McElnay J.C., Scott M.G., McConnell J.B. Management of Helicobacter pylori eradication - the influence of structured counselling and follow-up. Br. J. Clin. Pharmacol. (2002) 53 163-171.
23. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Practice & Research Clinical Gastroenterology (2001) 15 413-431.
24. Graham D.Y., Rakel R.E., Fendrick A.M. et al. Practical advice on eradicating Helicobacter pylori infection. Postgrad. Med. (1999) 105 137-143.
25. Maton P., Burton M. Clinician's manual on drug interactions in gastroenterology, Life Science Communications Ltd, London, 1996.
26. Sheu B.S., Huang J.J., Yang H.B. et al. The selection of triple therapy for Helicobacter pylori eradication in chronic renal insufficiency. Aliment. Pharmacol. Ther. (2003) 17 1283-1290.
27. De Boer W.A., Tytgat NJ. Treatment of Helicobacter pylori infection. Br Med J (2001) 320 31-34.
28. Meurer L.N., Bower D.J. Management of Helicobacter pylori infection. Am. Family Physician. (2002) 65 1327-1336, 1339.
29. Vallve M., Vegara M., Gispert J.P., Calvet X. Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta analysis. Aliment. Pharmacol. Ther. (2002) 16 1149-1156.
30. Wu J.C., Sung J.J.Y. Ulcer and gastritis. Endoscopy (2002) 34 104-110.
31. Shaffer D.N., Datta S.K., Matchar D.B. Cost effectiveness of abbreviated regimens for Helicobacter pylori eradication in peptic ulcer disease. JCOM (2002) 9 71-78.
32. Bazzoli F. Key points from the revised Maastricht Consensus Report: the impact on general practice. Eur. J. Gastroenterol. Hepatol. (2001) 13 S3-S7.
33. Vanderhoff B.T., Tahbou R.M. Proton pump inhibitors: an update. Am. Family Physician (2002) 66 273-280.
34. Huang J.Q., Hunt R.H. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician. Best Practice & Research Clinical Gastroenterology (2001) 15 355-370.
35. Gustavson L.E., Kaiser J.F., Edmonds A.L. et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob. Agents Chemother. (1995) 39 2078-2083.
36. Lozniewski A., de Korwin J.D., Muhale F., Jehl F. Gastric diffusion of antibiotics used against Helicobacter pylori. Int. J. Antimicrob. Agents (1998) 9 181-193.
37. Qasim A., O'Morain C.A. Review article: treatment of Helicobacter pylori infecton and factors influencing eradication. Aliment. Pharmacol. Ther. (2002) 16 24-30
38. Poon S.K., Chang C.S., Su J. et al. Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies. Aliment. Pharmacol. Ther. (2002) 16 291-296.
39. Gispert J.P., Pajares J.M. Review article: Helicobacter pylori rescue regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. (2002) 16 1047-1057.
40. Calvet X., Ducons J., Guardiola J, et al. One week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial. Aliment. Pharmacol. Ther. (2002) 16 1261-1267.
41. Lamouliatte H., Mégraud F., Delchier J.C. et al. Second-line eradication of Helicobacter pylori after failure of an initial treatment: a randomized prospective study comparing four treatment strategies. Gut (2001) 49 (Suppl. 2) A83 15/01.
42. Mégraud F., Lamouliatte H., Delchier J.C. et al. Helicobacter pylori resistance to antimicrobial agents after failure of an initial eradication treatment and impact on results of second line treatment strategies: a multicenter prospective study. Gut (2001) 49 (suppl. 2) A83 15/03.
43. Mégraud F., Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment. Pharmacol. Ther. (2003) 17 1333-1343.
44. Zullo A., Hassan C., Lorenzetti R, et al. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Digestive and Liver Disease (2003) 35 357-361.
45. Guslandi M. Review article: alternative antibacterial agents for Helicobacter pylori eradication. Aliment. Pharmacol. Ther. (2001) 15 1543-1547.
46. Wilson I., Långström G., Wahlqvist P, et al. Management of gastroduodenal ulcers and gastrointestinal symptoms associated with nonsteroidal anti-inflammatory drug therapy: a summary of four comparative trials with omeprazole, ranitidine, misoprostol, and placebo. Curr. Ther. Res. Clin. Exp. (2001) 62 835-850.
47. Graumlich J.F. Preventing gastrointestinal complications of NSAIDs. Risk factors, recent advances, and latest strategies. Postgrad. Med. (2001) 109 117-128.
48. Lai K.C., Lau C.S., Ip W.Y. et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double blind, placebo controlled trial. Aliment. Pharmacol. Ther (2003) 17 799-805.
49. Chan F.K., To K.F., Wu C.Y. et al. Eradication of Helicobacter pylori and risk of peptic ulcer in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet (2002) 359 9-13.
50. Micklewright R., Lane S., Linley W, et al. Review article: NSAIDs, gastroprotection and cyclo-oxygenase-II selective inhibitors. Aliment. Pharmacol. Ther. (2003) 17 321-332.
51. Silverstein F.E., Faich G., Goldstein J.L. et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celexocib Long-term Arthritis Safety Study. JAMA (2000) 284 1247-1255.
52. Bombardier C., Laine L., Reicin A, et al. Comparison of upper gastrointestinal toxicity of refocoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. (2000) 343 1520-1528.
53. Wolfe F., Anderson J., Burke T.A. et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J. Rheumatol. (2002) 29 467-473.
54. Palmer R.H., Bras P., Buchner A., Elsaesser R. Licofelone (ML3000) an inhibitor of COX-1, COX-2 and 5-LO, is associated with less gastric damage than naproxen and is similar to placebo in man. Gastroenterology (2002) 122 (Suppl. 1) A-54.
55. Yeomans N.D., Hawkey C., Lanas A, et al. Prevalence of gastric and duodenal ulcers during 'low dose' aspirin. Gastroenterology. (2002) 122 (Suppl. 1) A-87.
56. Chan F.K., Chung S.C., Suen B.Y. et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. (2001) 344 967-973.
57. Lai K.C., Lam S.K., Chu K.M. et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N. Engl. J. Med. (2002) 346 2033-2038.
58. Chan F.K.L., Leung W.K. Peptic ulcer disease. Lancet (2002) 360 933-941.
59. Graham D.Y. Large U.S. Clinical trials report a high proportion of H. pylori negative duodenal ulcers at study entry as well as a high recurrence rate after cure of infection: have we all been wrong? Gastroenterology (1998) 114 17.
60. Howden C.W. What causes Helicobacter pylori-negative non-NSAID related ulcers?. in: Hunt R.H.. Tytgat G.N.J. (Eds). Helicobacter pylori: basic mechanisms to clinical cure 2000, Kluwer Academic Publishers, London, 2000, pp. 339-345.
61. Lanas A., Remacha B., Sáinz R., Hirschowltz B.I. Study of outcome after targeted intervention for peptic ulcer resistant to acid suppression therapy. Am. J. Gastroenterol. (2000) 95 513-519.
62. Freston J.W. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment. Pharmacol. Ther. (2001) 152-5.
63. Hobsley M., Tovey F.I. Helicobacter pylori: the primary cause of duodenal ulceration or a secondary infection. World J. Gastroenterol. (2001) 7 149-151.
64. Quan C., Talley N.J. Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs. Am. J. Gastroenterol. (2002) 97 2950-2961.